Notice Number: NOT-HG-19-011
Key Dates
Release Date:January 22, 2019
RFA-HG-18-001
RFA-HG-18-002
RFA-HG-18-003
Issued by
National Human Genome Research Institute (NHGRI)
Purpose
As a companion effort to the Genome Reference Consortium Funding Opportunity Announcements cited above, NHGRI seeks to provide additional support for comprehensive telomere to telomere sequencing technology development with novel methods under the existing Novel Nucleic Acid Sequencing Technology Development RFAs.
- RFA-HG-18-001: Novel Nucleic Acid Sequencing Technology Development (R01 Clinical Trial Not Allowed)
- RFA-HG-18-002: Novel Nucleic Acid Sequencing Technology Development (R21 Clinical Trial Not Allowed)
- RFA-HG-18-003: Novel Nucleic Acid Sequencing Technology Development (R43/R44 Clinical Trial Not Allowed)
For each of these FOAs: RFA-HG-18-001, RFA-HG-18-002, RFA-HG-18-003
Objectives:
Currently Reads:
For DNA sequencing, novel methods that generate large numbers of long reads of high quality with a low cost are sought. New physical or chemical detection methods for sequencing are especially encouraged along with substantive (no less than an order of magnitude) improvement to current high-throughput DNA sequencing technologies. Those methods that yield novel sequence-based insights or that solve existing limitations in the field (e.g., de novo assembly of phased human genomes, direct determination of multiple and specific base modifications, complete and quantitative sequencing of all the DNA in a sample, essentially complete genomes of single cells, very small quantities of starting material down to a single cell, long reads of at least 150Kb to a megabase or more, etc.) are of especially high interest.
Modified to Read:
For DNA sequencing, novel methods that generate large numbers of long reads of high quality with a low cost are sought. New physical or chemical detection methods for sequencing are especially encouraged along with substantive (no less than an order of magnitude) improvement to current high-throughput DNA sequencing technologies. Those methods that yield novel sequence-based insights or that solve existing limitations in the field (e.g., de novo assembly of phased human genomes, direct determination of multiple and specific base modifications, complete and quantitative sequencing of all the DNA in a sample, essentially complete genomes of single cells, very small quantities of starting material down to a single cell, long reads of at least 150Kb to a megabase or more, comprehensively determine genomic sequence from telomere to telomere in a manner that ideally is phased, or develop generalized approaches to sequence unresolved complex regions of the genome in a manner that ideally are phased, etc.) are of especially high interest.
For RFA-HG-18-001:
Funds Available and Anticipated Number of Awards:
Currently Reads:
NHGRI intends to commit $1,500,000 in FY19, FY 20 and FY 21 to fund 2-4 awards yearly.
Modified to Read:
NHGRI intends to commit $1,500,000 in FY19 and FY21 to fund 2-4 awards each year, and $2,300,000 in FY20 to fund 3-6 awards.
For RFA-HG-18-002:
Funds Available and Anticipated Number of Awards:
Currently Reads:
NHGRI intends to commit $500,000 in each of FY19, FY 20 and FY 21 to fund 2-4 awards yearly.
Modified to Read:
NHGRI intends to commit $500,000 in each of FY19 and FY21 to fund 2-4 awards each year, and $1,200,000 in FY 20 to fund 4-6 awards.
For RFA-HG-18-003:
Funds Available and Anticipated Number of Awards:
Currently Reads:
NHGRI intends to commit $1,500,000 in each of FY19, FY 20 and FY 21 to fund 2-4 awards yearly.
Modified to Read:
NHGRI intends to commit $1,500,000 in each of FY19 and FY 21 to fund 2-4 awards each year, and $2,250,000 in FY20 to fund 3-6 awards.
All other aspects of these FOAs remain unchanged.
Inquiries
Please direct all inquiries to:
Division of Genome Sciences
National Human Genome Research
Telephone: 301-480-3413
Email: [email protected]
and Human Services (HHS)
